

Hull and East Riding Prescribing Committee Minutes – Unconfirmed

Date / Time Wednesday 23th March 2022, 1pm
Venue WEBEX
Chair Dr S Raise, GP Prescribing Lead, ERY CCG
Notes / Action Points Mr Luke Storr, Senior Technician – Interface HUTH
Quorate: Yes / No Yes

Miss J Morgan, Principal Pharmacist - Interface, HUTH
Dr B Ali, GP Prescribing Lead, ER CCG
Mrs G McNally, Senior Pharmacist CHCP
Mr K McCorry, Senior Pharmacist, NECS
Ms M Opoku-Fofie, Deputy Chief Pharmacist, HFTH
Prof A Morice, Professor of Respiratory Medicine, HUTH
Mrs C Haywood, Professional Development Lead, LPC
Mrs E Wise, Pharmacy Manager, Spire Hull and East Riding
Ms J Goode, Chief Pharmacist, HUTH

Apologies Mr P Davis, Strategic Lead Primary Care, Hull, CCG

Dr R Schreiber, Professional Secretary LMC

Mrs E Baggaley, Head of Medicines Service, CHCP

In attendance Luke Storr, Interface Technician, HUTH

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
2022.03.01	Apologies	As above				
2022.03.02	Declarations of Interest	None				
2022.03.03	Minutes of the Previous Meeting	Accepted as a true record				
2022.03.04	Matters Arising & Action Tracker	<p>Correspondence Received Rheumatology to prepare pathway with rituximab without MTX- Pathway still in draft form- Rheumatology pharmacist to meet with Dr Ogumbambi and confirm pathway</p> <p>Feedback From Commissioning Groups KMc and JM to work with CCG to approve MS guideline- JM/Dr Harley to attend pathway review group and feedback</p> <p>Hydroxychloroquine SCF JM to discuss ophthalmology checks with rheumatology. JM to add Harrogate pathway to agenda when published.</p> <p>Traffic Light Status JM to update formulary and red list</p> <p>Prescribing guidelines, shared care frameworks for approval JM to confirm with LMC position on antenatal and postnatal dalteparin. Confirmed position with LMC</p> <p>Prescribing guidelines, shared care frameworks for approval JM to update commissioning position of anticoagulants to reflect position on antenatal and postnatal care. Updated and sent to web services.</p> <p>Prescribing guidelines, shared care frameworks for approval JM to update rosacea pathway regarding referral to secondary care for transient facial flushing. Updated and sent to web services.</p> <p>AOB Diabetes guideline – JM to review diabetes guideline when NICE publish and discuss with Diabetologists- Discussion internally ongoing</p>	<p>Update next time</p> <p>Update next time</p> <p>Awaiting Harrogate to publish pathway</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Action complete</p> <p>Await new guidance then update further</p>	<p>Ongoing</p> <p>Ongoing</p> <p>Ongoing</p> <p>No further actions</p> <p>No further actions</p> <p>No further actions</p> <p>No further actions</p> <p>Ongoing</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p>	<p>Apr 22</p> <p>Aug 22</p> <p>Sep 21</p> <p>Mar 22</p> <p>Mar 22</p> <p>Mar 22</p> <p>Mar 22</p> <p>Mar 22</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>Traffic Light Status JM to update formulary and red list</p> <p>Prescribing guidelines – UTI guidance JM to update current guidance to remove old UTI guidance and add new guidance to website. JM to finish</p> <p>Prescribing guidelines – Dienogest pathway JM to confirm prescribing arrangements with specialist team. JM received no great response from prescribers. Red until updated pathway</p> <p>Prescribing guidelines – Secondary prevention pathways for lipid lowering therapies JM to if LDL-C is needed before the specialist referral and to prepare SCF for Inclisiran in conjunction with specialist team- On agenda, JM has started preparing guidance.</p> <p>Prescribing guidelines - Renal analgesic ladder To upload on HERPC website with web services</p> <p>Prescribing guidelines – update ticagrelor 60mg To upload on HERPC website with web services</p> <p>Prescribing guidelines - Prescribing medicines in pregnancy To remove old prescribing guideline in pregnancy and update webpage with SPS information and disclaimer regarding HUTH guidance. Not sent to web service yet, awaiting other documents to be uploaded.</p> <p>Prescribing guidelines – Renal transplant medicines JM to update with alternative H2 receptor antagonist and review plan for renal repatriation. JM spoken to renal, renal gave counter active response. JM to feedback to renal and discuss with NHSE.</p>	<p>Action complete</p> <p>JM to complete before next meeting</p> <p>To update pathway</p> <p>On agenda</p> <p>Action complete</p> <p>Action complete</p> <p>Ongoing</p> <p>Ongoing</p>	<p>No further actions</p> <p>Update next time</p> <p>Update next time</p> <p>Update next time</p> <p>No further actions</p> <p>No further actions</p> <p>Update next time</p> <p>Update next time</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p> <p>JM</p>	<p>Mar 22</p> <p>Mar 22</p> <p>Mar 22</p> <p>Apr 22</p> <p>Mar 22</p> <p>Mar 22</p> <p>Mar 22</p> <p>Apr 22</p>
2022.03.05	Traffic Light Status	<p>Cenobamate- Proposed as BLUE</p> <p>Ponesimod- Proposed as RED (Homecare)</p> <p>Clonidine patches (unlicensed medicine)- Proposed as RED</p> <p>Azithromycin- Proposed as BLUE</p>	Approved	RED list to be updated and joint formulary to be updated	LS	Mar 22
2022.03.06	Feedback From Commissioning	<p>Hull CCG- Traffic light status Jan 2022 approved</p> <p>Primary care guidelines UTI- agreed</p>	Noted	No further action		Mar 22

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
	Groups	DOACs- commissioning for DOACs agreed				
2022.03.07	Prescribing guidelines, shared care frameworks for approval	<p>NEW:</p> <p>a) HUTH lipid guidance – JM presented the new HUTH lipid guidance which also contains the secondary prevention pathway which includes inclisiran. Currently inclisiran is in the pathway on recommendation of the specialist lipid team however in future envisaged that primary care could initiate this. Suggested to give a 6-month review date. There is also an inclisiran prescribing guidance to complement this that will be presented at next meeting.</p> <p>Updates:</p> <p>b) CHCP community frailty COVID 19 guidance- GMc presented this guidance that the CHCP frailty team have been using and has been prepared in conjunction with the HUTH infectious disease team. It contains summary of treatment and can be used with the advice provided by frailty team. Approved</p> <p>c) CHCP paediatric nutrition support guidance- Appendix on multivitamins needs updated with only formulary lines included. Approved subject to updated table</p> <p>d) CHCP wound management guidance – The CHCP wound management guidance has been updated and the budget and prescribing is within the clinical team. KMc question where the team FP10 was costed and GMc will confirm. Approved subject to confirmation.</p> <p>e) CHCP compression formulary- GMc presented this updated guidance. The budget sits within the team and prescribing sits in team as well. KMc requested conformation where the FP10 was costed and GMc will confirm. BA raised compression aids and if there was a tool the team used to assess this. GMc will confirm. Approved subject to confirmation.</p> <p>Pathway updates</p> <p>f) Systemic Biological Therapy for Psoriatic Arthritis- JM presented updates to this dermatology pathway. It had been updated with new TAs and the psoriasis and psoriatic arthritis pathway separated. Mechanism of action had been added to aid consideration mechanism of action on sequential use. KMc requested that reference to the RMOC document on sequential use of biologics added. Approved with amendment</p>	<p>Approved</p> <p>Approved</p> <p>Approved subject to minor changes</p> <p>Approved subject to confirmation</p> <p>Approved subject to confirmation</p> <p>Approved with addition of reference</p>	<p>Add to website and add inclisiran guidance to next months agenda</p> <p>To upload to HERPC COVID guidance</p> <p>To upload to web when updated</p> <p>To update next time</p> <p>To update next time</p> <p>To add to website</p>	<p>JM</p> <p>JM</p> <p>JM</p> <p>GMc</p> <p>GMc</p> <p>JM</p>	<p>Mar 22</p> <p>Mar 22</p> <p>Apr 22</p> <p>Apr 22</p> <p>Apr 22</p> <p>Apr 22</p>

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date/Date complete
		<p>g) Systemic Biological Therapies for Psoriasis- JM presented updates on this pathway, which included addition of new TAs, including mechanisms of action in pathways and change in positioning of biosimilar biologics. KMc requested reference to RMOC document as above and clarity on how they choose between the 4 first line options (oral therapy or biosimilar biologic)</p> <p>h) Systemic Biological Therapy for Eczema- JM presented updated pathway for atopic dermatitis, which has been updated with new TA and addition of mechanisms of action for biologics. To add RMOC reference as above. Approved with amendment</p>	<p>JM to request info on first choices</p> <p>Approved with addition of reference</p>	<p>To update next time</p> <p>To add to website</p>	<p>JM</p> <p>JM</p>	<p>Apr 22</p> <p>Apr 22</p>
2022.03.08	MHRA DSU	<ul style="list-style-type: none"> January February 	Noted	No further action		Mar 22
2022.03.09	Regional Medicines Optimisation Committee	Nil this month	Noted	No further action		Mar 22
2022.03.10	Correspondence Received	Nil this month	Noted	No further action		Mar 22
2022.03.11	Primary Care Rebate Scheme	Hull CCG Physeptone (methadone) and Espanor (Buprenorphine)	Noted	No further action		Mar 22
2022.03.12	Additional Minutes for Information	<p>a) MMIG (Feb)</p> <p>b) HUTH D&T (Feb)</p> <p>c) HTFT DTC (Nov)</p> <p>d) CHCP</p> <p>e) Formulary Sub Group</p> <p>f) Hull CC Planning & Commissioning</p>	Noted	No further action		Mar 22
2022.03.13	A.O.B	<ul style="list-style-type: none"> Another meeting before passing over to the next committee. Agreed to have a closure meeting then pass over to APC group 				
	Date and Time of Next Meeting	Wednesday 27 th April 2022, 1pm, WEBEX				